US2015231158A1PendingUtilityA1

Novel oxime derivatives as sphingosine 1-phosphate (s1p) receptor modulators

Assignee: ALLERGAN INCPriority: Dec 3, 2010Filed: May 5, 2015Published: Aug 20, 2015

Est. expiryDec 3, 2030(~4.3 yrs left)· nominal 20-yr term from priority

Inventors:Wenkui K. Fang Liming Wang Evelyn G. Corpuz Ken Chow Whabin Im

A61P 9/10A61P 35/04A61P 7/10A61P 37/06A61P 43/00A61P 5/16A61P 9/00A61P 37/08A61P 37/00A61P 27/02A61P 29/00A61P 25/04A61P 27/06A61P 31/04A61P 17/00C07F 9/3808A61P 13/12C07C 229/34A61P 1/00A61K 31/197A61P 19/02A61P 1/04A61P 21/00A61K 31/662A61P 17/02A61P 17/06A61P 25/00A61P 19/00C07F 9/3834A61P 19/10A61P 1/02A61P 11/06A61P 11/00A61P 21/04C07F 9/38

PatentIndex Score

Cited by

References

Claims

Abstract

The present invention relates to novel oxime derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.

Claims

exact text as granted — not AI-modified

What is claimed is: 
     
         1 . A method of treating multiple sclerosis in a mammal in need of such treatment, the method comprising administering to the mammal a pharmaceutical composition comprising a therapeutically effective amount of at least one compound selected from the group consisting of:
 3-({4-[({[(1E)-2-(3,5-difluorophenyl)-3-(3,4-dimethylphenyl)-1-methylpropylidene]amino}oxy)methyl]benzyl}amino)propanoic acid;   [3-({4-[({[(1E)-2-(3,5-difluorophenyl)-3-(3,4-dimethylphenyl)-1-methylpropylidene]amino}oxy)methyl]benzyl}amino)propyl]phosphonic acid;   [3-({4-[({[(1E)-2-(3-chlorophenyl)-3-(3,4-dimethylphenyl)-1-methylpropylidene]amino}oxy)methyl]benzyl}amino)propyl]phosphonic acid;   3-[(4-{(1E)-N-[3-(3,4-dimethylphenyl)-2-(3-methylphenyl)propoxy]ethanimidoyl}benzyl)amino]propanoic acid;   3-[(4-{(1E)-N-[2-(3-chlorophenyl)-3-(3,4-dimethylphenyl)propoxy]ethanimidoyl}benzyl)amino]propanoic acid;   {3-[(4-{(1E)-N-[2-(3-chlorophenyl)-3-(3,4-dimethylphenyl)propoxy]ethanimidoyl}benzyl)amino]propyl}phosphonic acid;   {3-[(4-{(1E)-N-[3-(3,4-dimethylphenyl)-2-(3-methylphenyl)propoxy]ethanimidoyl}benzyl)amino]propyl}phosphonic acid;   [3-({4-[(1E)-N-{2-[(3,4-dimethylphenyl)sulfonyl]-2-(3-fluorophenyl)ethoxy}ethanimidoyl]benzyl}amino)propyl]phosphonic acid;   3-({4-[(1E)-N-{2-[(3,4-dimethylphenyl)thio]-2-(3-fluorophenyl)ethoxy}ethanimidoyl]benzyl}amino)propanoic acid;   {3-[(4-{[({(1E)-2-(3-chlorophenyl)-2-[(3,4-dimethylphenyl)thio]-1-methylethylidene}amino)oxy]methyl}benzyl)amino]propyl}phosphonic acid;   3-[(4-{[({(1E)-2-(3-chlorophenyl)-2-[(3,4-dimethylphenyl)thio]-1-methylethylidene}amino)oxy]methyl}benzyl)amino]propanoic acid;   3-({4-[({[(1E)-2-(3-chlorophenyl)-2-(3,4-dimethylphenoxy)-1-methylethylidene]amino}oxy)methyl]benzyl}amino)propanoic acid;   [3-({4-[({[(1E)-2-(3-chlorophenyl)-2-(3,4-dimethylphenoxy)-1-methylethylidene]amino}oxy)methyl]benzyl}amino)propyl]phosphonic acid;   3-[(4-{(1E)-N-[2-(3-chlorophenyl)-2-(3,4-dimethylphenoxy)ethoxy]ethanimidoyl}benzyl)amino]propanoic acid; and   {3-[(4-{(1E)-N-[2-(3-chlorophenyl)-2-(3,4-dimethylphenoxy)ethoxy]ethanimidoyl}benzyl)amino]propyl}phosphonic acid.   
     
     
         2 . The method according to  claim 1 , wherein the pharmaceutical composition further comprises pharmaceutically acceptable adjuvants, diluents or carriers. 
     
     
         3 . The method according to  claim 1 , wherein the mammal is a human.

Join the waitlist — get patent alerts

Track US2015231158A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.